A phase 2 trial of imatinib mesylate in patients with recurrent nonresectable chondrosarcomas expressing platelet-derived growth factor receptor-α or -β

Imatinib plus low-dose doxorubicin in patients with advanced gastrointestinal stromal tumors refractory to high-dose imatinib

(2010) Joan Maurel et al.   CANCER

Kinome Profiling of Chondrosarcoma Reveals Src-Pathway Activity and Dasatinib as Option for Treatment

(2009) Y. M. Schrage et al.   CANCER RESEARCH

Genomic Profiling of Chondrosarcoma: Chromosomal Patterns in Central and Peripheral Tumors

(2009) K. H. Hallor et al.   CLINICAL CANCER RESEARCH

COX-2 expression in chondrosarcoma: A role for celecoxib treatment?

(2009) Y.M. Schrage et al.   EUROPEAN JOURNAL OF CANCER

Mesenchymal chondrosarcoma of soft tissues and bone in children, adolescents, and young adults

(2008) Tobias M. Dantonello et al.   CANCER

Phase II Study of High-Dose Photon/Proton Radiotherapy in the Management of Spine Sarcomas

(2008) Thomas F. DeLaney et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Heterogeneity of kinase inhibitor resistance mechanisms in GIST

(2008) B Liegl et al.   JOURNAL OF PATHOLOGY

The Clinical Approach Towards Chondrosarcoma

(2008) H. Gelderblom et al.   ONCOLOGIST

Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors

(2008) C. Tarn et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA